CA2188841A1 - Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders - Google Patents

Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders

Info

Publication number
CA2188841A1
CA2188841A1 CA002188841A CA2188841A CA2188841A1 CA 2188841 A1 CA2188841 A1 CA 2188841A1 CA 002188841 A CA002188841 A CA 002188841A CA 2188841 A CA2188841 A CA 2188841A CA 2188841 A1 CA2188841 A1 CA 2188841A1
Authority
CA
Canada
Prior art keywords
treatment
sequelae
blood supply
carbonylaminobenzene
fluorobenzylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002188841A
Other languages
French (fr)
Other versions
CA2188841C (en
Inventor
Angelika Rostock
Chris Rundfeldt
Christine Tober
Reni Bartsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Publication of CA2188841A1 publication Critical patent/CA2188841A1/en
Application granted granted Critical
Publication of CA2188841C publication Critical patent/CA2188841C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The use of the compound I
CA002188841A 1995-10-26 1996-10-25 Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders Expired - Fee Related CA2188841C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539861.0 1995-10-26
DE19539861A DE19539861A1 (en) 1995-10-26 1995-10-26 Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CA2188841A1 true CA2188841A1 (en) 1997-04-27
CA2188841C CA2188841C (en) 2006-05-23

Family

ID=7775835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002188841A Expired - Fee Related CA2188841C (en) 1995-10-26 1996-10-25 Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders

Country Status (26)

Country Link
US (2) US5852053A (en)
EP (1) EP0857065B1 (en)
JP (2) JP4567101B2 (en)
KR (1) KR100423823B1 (en)
AR (1) AR004108A1 (en)
AT (1) ATE178487T1 (en)
AU (1) AU706735B2 (en)
BR (1) BR9610899A (en)
CA (1) CA2188841C (en)
CZ (1) CZ291456B6 (en)
DE (2) DE19539861A1 (en)
DK (1) DK0857065T3 (en)
ES (1) ES2131973T3 (en)
GR (1) GR3030336T3 (en)
HU (1) HU228014B1 (en)
ID (1) ID16489A (en)
IL (1) IL123523A (en)
NO (1) NO316493B1 (en)
NZ (1) NZ326754A (en)
PL (1) PL185714B1 (en)
RU (1) RU2201227C2 (en)
SK (1) SK283222B6 (en)
TW (1) TW457084B (en)
UA (1) UA51681C2 (en)
WO (1) WO1997015300A2 (en)
ZA (1) ZA968991B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (en) * 1995-10-26 1997-04-30 Asta Medica Ag Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
UA79666C2 (en) * 2002-12-27 2007-07-10 Lundbeck & Co As H 1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders
ATE357438T1 (en) 2002-12-27 2007-04-15 Lundbeck & Co As H 1,2,4-TRIAMINOBENZENE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CN101563085A (en) * 2006-08-23 2009-10-21 威朗国际制药公司 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (en) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 Kcnq potassium channel agonist, Preparation Method And The Use that one class is novel
EP2882429B1 (en) * 2012-08-07 2024-04-10 The General Hospital Corporation Potassium-channel openers for use in treating amyotrophic lateral sclerosis (ALS)
CN105017085B (en) 2014-04-28 2018-06-29 中国科学院上海药物研究所 A kind of kcnq potassium channel agonist, preparation method and use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817334B2 (en) * 1990-03-29 1998-10-30 株式会社ツムラ Nerve cell protective agent
DE4200259A1 (en) * 1992-01-08 1993-07-15 Asta Medica Ag NEW 1,2,4-TRIAMINOBENZOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DE4327516A1 (en) * 1993-08-17 1995-02-23 Asta Medica Ag Primary and secondary neuroprotective effects in neurodegenerative diseases of flupirtine
TW280819B (en) * 1993-11-17 1996-07-11 Sumitomo Pharma
DE19539861A1 (en) * 1995-10-26 1997-04-30 Asta Medica Ag Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases

Also Published As

Publication number Publication date
HU228014B1 (en) 2012-08-28
EP0857065A2 (en) 1998-08-12
PL325956A1 (en) 1998-08-17
IL123523A0 (en) 1998-10-30
CZ291456B6 (en) 2003-03-12
WO1997015300A2 (en) 1997-05-01
ATE178487T1 (en) 1999-04-15
CA2188841C (en) 2006-05-23
ZA968991B (en) 1997-06-10
DE19539861A1 (en) 1997-04-30
DE59601624D1 (en) 1999-05-12
WO1997015300A3 (en) 1997-07-03
JP4567101B2 (en) 2010-10-20
EP0857065B1 (en) 1999-04-07
AU1540097A (en) 1997-05-15
ES2131973T3 (en) 1999-08-01
NZ326754A (en) 2000-03-27
AR004108A1 (en) 1998-09-30
HUP9900508A2 (en) 1999-06-28
SK52098A3 (en) 1998-09-09
US5849789A (en) 1998-12-15
TW457084B (en) 2001-10-01
UA51681C2 (en) 2002-12-16
HUP9900508A3 (en) 1999-11-29
SK283222B6 (en) 2003-03-04
JP2009007366A (en) 2009-01-15
KR100423823B1 (en) 2004-08-25
DK0857065T3 (en) 1999-10-18
IL123523A (en) 2001-12-23
NO316493B1 (en) 2004-02-02
US5852053A (en) 1998-12-22
ID16489A (en) 1997-10-02
CZ122598A3 (en) 1998-09-16
AU706735B2 (en) 1999-06-24
BR9610899A (en) 1999-07-13
NO981503L (en) 1998-04-02
PL185714B1 (en) 2003-07-31
GR3030336T3 (en) 1999-09-30
NO981503D0 (en) 1998-04-02
MX9803172A (en) 1998-09-30
JPH11515007A (en) 1999-12-21
RU2201227C2 (en) 2003-03-27
KR19990067021A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
CA2188841A1 (en) Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders
EP0441119A3 (en) The use of l-arginine in the treatment of hypertension and other vascular disorders
EP2329829A3 (en) Use of uridine in combination with choline for the treatment of memory disorders
IT9021430A0 (en) TIGHTENING CLAMP WITHOUT EARS PRESENTING ELASTICITY IN THE LONGITUDINAL DIRECTION
BR0111913A (en) Gabapentin analogs for sleep disorders
USD279406S (en) Massage roller
USD319287S (en) Magnetic water treatment device
USD331358S (en) Cable clip
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
WO1998010762A3 (en) Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
CA2028514A1 (en) Treatment of depression
USD403346S (en) Eyeglass retainer
ITBO970579A0 (en) DEVICE FOR THE ELIMINATION OF HAIR AND/OR FOR THE ATROPHYZATION OF HAIR LINES.
FR2708189B1 (en) Medical device, the device part and the sleeping table of which can be moved relative to each other.
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
ITRM910390A0 (en) USE OF PROPIONIL L-CARNITINE FOR THE RECOVERY OF MUSCLE TONE IN IMMOBILIZED SUBJECTS.
USD340106S (en) Purse ring for use in the fishing industry
IS5324A (en) (S) 2-Methylamino-2-phenyl-n-butyl 3,4,5-trimethoxy-benzoate, its use in the treatment of chronic pain
USD416787S (en) Threaded fastener
BR9801839A (en) Analgesic medication and application of (+) -0-demethyltramadol.
USD489920S1 (en) Buffet
Steck The keepers and reapers of contemporary American prison writing
ITRM910695A1 (en) USE OF L-CARNITINE IN PREGNANCY AT RISK.
AU2001223910A1 (en) Interferon-alpha use in the treatment of ewing's family of tumors
FI972637A0 (en) Use of vitamin K in the treatment of hyperthyroidism

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141027